Evidence map›Paper›PMID 29534061›Full record

ArticlePLoS neglected tropical diseases2018

Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease.

Edeltraud J Lenk, William K Redekop, Marianne Luyendijk, Christopher Fitzpatrick, Louis Niessen, Wilma A Stolk, Fabrizio Tediosi, Adriana J Rijnsburger, Roel Bakker, Jan A C Hontelez and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Ex Vivo Infection of Human Placental Explants byPathogens (Basel, Switzerland) · 2022
    Article
  10. Review
  11. Article
  12. Considerations for a sustainability framework for neglected tropical diseases programming.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021
    Article
  13. Article
  14. Review
  15. Financial Costs of the Zanzibar Elimination of Schistosomiasis Transmission Project.The American journal of tropical medicine and hygiene · 2020
    Article
  16. Review
  17. Article
  18. Article
  19. Congenital Transmission ofFrontiers in microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Edeltraud J LenkErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-2438-4371
William K RedekopErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Marianne LuyendijkErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Christopher FitzpatrickDepartment of control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Louis NiessenCentre for Applied Health Research and Delivery, Department of International Public Health, Liverpool School of Tropical Medicine and University of Liverpool, Liverpool, United Kingdom.
Wilma A StolkDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Fabrizio TediosiSwiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.
Adriana J RijnsburgerMedical Delta, TU Delft, Delft, The Netherlands.
Roel BakkerDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jan A C HontelezDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jan H RichardusDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Julie JacobsonGlobal Health Program, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Epke A Le RutteDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Sake J de VlasDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Johan L SeverensErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Erasmus MC · NLErasmus University Rotterdam · NLDelft University of Technology · NLGates Foundation · USSwiss Tropical and Public Health Institute · CHUniversity of Liverpool · GBWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM).

methodsA systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011-2020 and 2021-2030. The ideal scenario in which the WHO's 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate.

resultsThe total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 -I$ 34.0) billion in 2011-2020 and I$ 35.9 (I$ 25.0 -I$ 51.9) billion in 2021-2030 (2.5th and 97.5th percentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 -US$ 15.7) and US$ 16.6 billion (US$ 11.6 -US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods.

conclusionsWe faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world's prosperity more equitably and reduce inequity.

Indexed as

Disease EradicationDisease ManagementGlobal HealthHealth ExpendituresHumansNeglected DiseasesPovertyReview Literature as Topic

Identifiers

PMID29534061
PMCPMC5849290
OpenAlexW2792221349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.